Kavar Capital Partners Group’s Nektar Therapeutics NKTR Stock Holding History

Kavar Capital Partners Group’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-83	Closed	-$44K	–	341
2019 Q2	$44K	Buy	+83	New	+$41.6K	0.02%	239
2018 Q3	–	Sell	-83	Closed	-$61K	–	287
2018 Q2	$61K	Hold	83	–	–	0.03%	168
2018 Q1	$133K	Buy	+83	New	+$107K	0.07%	128
2016 Q1	–	Sell	-117	Closed	-$29K	–	287
2015 Q4	$29K	Hold	117	–	–	0.02%	199
2015 Q3	$19K	Sell	117 -50	-30%	-$8.85K	0.01%	234
2015 Q2	$31K	Buy	+167	New	+$28.7K	0.02%	209
2014 Q2	–	Sell	-168	Closed	-$30K	–	332
2014 Q1	$30K	Buy	168 +1	+0.6%	+$198	0.02%	228
2013 Q4	$28K	Buy	+167	New	+$26.9K	0.03%	224

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kavar Capital Partners Group's NKTR Position: Q3 2019 in Review

Kavar Capital Partners Group sold out of Nektar Therapeutics (NKTR) in Q3 2019, closing a stake of 83 shares — an estimated $44K sold.

Kavar Capital Partners Group first reported a position in NKTR in Q4 2013 and held it in 8 quarters. The position peaked at $133K in Q1 2018. 287 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

Kavar Capital Partners Group reported no remaining Nektar Therapeutics position as of Q3 2019 after selling out during the quarter.
Kavar Capital Partners Group sold 83 Nektar Therapeutics shares in Q3 2019, an estimated $44K.
Kavar Capital Partners Group first reported a position in Nektar Therapeutics in Q4 2013 and held it in 8 quarters.
Kavar Capital Partners Group's Nektar Therapeutics position peaked at $133K in Q1 2018.
287 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on Kavar Capital Partners Group's 13F filing for Q3 2019, filed 12 Nov 2019.